Nikibakhsh Ahmad Ali, Mahmoodzadeh Hashem, Karamyyar Mohamad, Hejazi Sasan, Noroozi Mehran, Macooie Ali Agayar
Urmia University School of Medicine, Urmia, Iran.
Saudi J Kidney Dis Transpl. 2014 Jul;25(4):858-63. doi: 10.4103/1319-2442.135182.
Henoch-Schonlein purpura (HSP) is the most common childhood vasculitis. Renal involvement in HSP is one of the major causes of chronic renal failure in children. It is important to start effective and relatively safe medication to prevent end-stage renal disease (ESRD). Mycophenolate mofetil (MMF) appears to be a promising therapeutic agent in many autoimmune diseases such as lupus nephritis and vasculitis. Herein, we describe the treatment with MMF of three patients with HSP nephritis. In two cases with rapidly progressive glomerulonephritis without response to steroid, after treatment with MMF, significant improvement in kidney function and proteinuria were observed. In another patient with HSP nephritic-nephrotic syndrome who showed resistance to steroid, MMF offered a favorable effect. MMF seems to be a promising therapeutic agent in the treatment of the severe HSP nephritis.
过敏性紫癜（HSP）是儿童最常见的血管炎。HSP的肾脏受累是儿童慢性肾衰竭的主要原因之一。启动有效且相对安全的药物治疗以预防终末期肾病（ESRD）很重要。霉酚酸酯（MMF）在许多自身免疫性疾病如狼疮性肾炎和血管炎中似乎是一种有前景的治疗药物。在此，我们描述了3例HSP肾炎患者使用MMF的治疗情况。在2例对类固醇无反应的快速进展性肾小球肾炎患者中，使用MMF治疗后，观察到肾功能和蛋白尿有显著改善。在另一例对类固醇耐药的HSP肾炎-肾病综合征患者中，MMF产生了良好效果。MMF似乎是治疗重症HSP肾炎的一种有前景的治疗药物。
